dextroamphetamine has been researched along with Aggression in 111 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Aggression: Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Under conditions of such high aggression, the previously reported pro-aggressive action of a low (5 mg/kg) dosage of chlordiazepoxide (CDP) is hardly detectable." | 7.67 | Maternal aggression towards different sized male opponents: effect of chlordiazepoxide treatment of the mothers and d-amphetamine treatment of the intruders. ( Mos, J; Olivier, B; van Oorschot, R, 1987) |
| "Two or 3 days after a single high-dose (20 mg/Kg) of p-chloroamphetamine (PCA) aggression was reliably observed in male mice." | 7.65 | Aggression in mice after p-chloroamphetamine. ( Gianutsos, G; Lal, H, 1975) |
| "Aggression, which is normally seen during withdrawal from narcotics, could not be produced in morphine-dependent rats by the administration of naloxone at doses which causes other signs of withdrawal." | 7.65 | Paradoxical absence of aggression during naloxone-precipitated morphine withdrawal. ( Drawbaugh, RB; Gianutsos, G; Hynes, MD; Lal, H, 1975) |
| " Levels of CSF 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG), the metabolites of serotonin, dopamine, and norepinephrine, respectively, correlated significantly with behavioral measures of aggression and impulsivity/hyperactivity." | 5.07 | Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. ( Castellanos, FX; Elia, J; Gulotta, CS; Kruesi, MJ; Mefford, IN; Potter, WZ; Rapoport, JL; Ritchie, GF, 1994) |
| " The anticonvulsant effect of caerulein (125 micrograms/kg) against picrotoxin (10 mg/kg) induced seizures was abolished after 14 days diazepam, but not after haloperidol, treatment." | 3.68 | Changes at cholecystokinin receptors induced by long-term treatment with diazepam and haloperidol. ( Harro, J; Lang, A; Soosaar, A; Vasar, E, 1992) |
| " Under conditions of such high aggression, the previously reported pro-aggressive action of a low (5 mg/kg) dosage of chlordiazepoxide (CDP) is hardly detectable." | 3.67 | Maternal aggression towards different sized male opponents: effect of chlordiazepoxide treatment of the mothers and d-amphetamine treatment of the intruders. ( Mos, J; Olivier, B; van Oorschot, R, 1987) |
| "Two or 3 days after a single high-dose (20 mg/Kg) of p-chloroamphetamine (PCA) aggression was reliably observed in male mice." | 3.65 | Aggression in mice after p-chloroamphetamine. ( Gianutsos, G; Lal, H, 1975) |
| "Aggression, which is normally seen during withdrawal from narcotics, could not be produced in morphine-dependent rats by the administration of naloxone at doses which causes other signs of withdrawal." | 3.65 | Paradoxical absence of aggression during naloxone-precipitated morphine withdrawal. ( Drawbaugh, RB; Gianutsos, G; Hynes, MD; Lal, H, 1975) |
| " Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks." | 2.74 | Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. ( Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2009) |
| " Two basic experimental designs were used: (a) dosage of amphetamine was varied, with duration of deprivation constant at 22 hr; and (b) deprivation was varied, with a constant amphetamine dose of 1." | 1.27 | Effects of interactions between amphetamine and food deprivation on covariation of muricide, consummatory behaviour and activity. ( Bowman, G; Russell, JW; Singer, G, 1983) |
| " d-Amphetamine, cocaine, and caffeine each had the effect of elevating both bite and lever press responses; nicotine, chlorpromazine, chlordiazepoxide, and diazepam each elevated lever press responding while depressing bite responding across a portion of the dosage range; phenobarbital, alcohol, and morphine had the effect of depressing both bite and lever press responses but lever pressing was selectively more depressed than biting." | 1.27 | Unique influences of ten drugs upon post-shock biting attack and pre-shock manual responding. ( Emley, GS; Hutchinson, RR, 1983) |
| "Thioridazine was variable across clients, settings, behaviors, and dosages." | 1.27 | Clinical behavioral pharmacology: methods for evaluating medications and contingency management. ( Burgio, LD; Capriotti, RM; Page, TJ, 1985) |
| "Hooded rats were injected with physiological saline or d-amphetamine sulfate for 13 days on a schedule designed to mimic patterns of abuse: one injection on days 1-11, two injections on day 12, and three injections on day 13; amphetamine dosage for the first three injections was 3." | 1.26 | Chronic amphetamine: effects on defensive flight in the rat. ( Mollenauer, S; Pipkin, B; Plotnik, R; White, M, 1982) |
| " Current observations of effects of acute and long-term chronic administration of delta9-tetrahydrocannabinol in group-caged rhesus monkeys are cited to demonstrate the sensitivity and specificity of primate social behavior test systems in characterization of CNS drugs." | 1.26 | Primate social behavior as a method of analysis of drug action: studies with THC in monkeys. ( Chapman, LF; Sassenrath, EN, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 99 (89.19) | 18.7374 |
| 1990's | 8 (7.21) | 18.2507 |
| 2000's | 4 (3.60) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blader, JC | 1 |
| Schooler, NR | 1 |
| Jensen, PS | 1 |
| Pliszka, SR | 1 |
| Kafantaris, V | 1 |
| CONSOLO, S | 3 |
| GARATTINI, S | 3 |
| VALZELLI, L | 4 |
| Galli, G | 1 |
| Wolffgramm, J | 1 |
| Benjamin, E | 1 |
| Salek, S | 1 |
| White, TL | 1 |
| Grover, VK | 1 |
| de Wit, H | 1 |
| Maletzky, BM | 1 |
| Salustiano, J | 1 |
| Hoshino, K | 1 |
| Carlini, EA | 1 |
| Weischer, ML | 1 |
| Olivier, B | 2 |
| van Aken, H | 1 |
| Jaarsma, I | 1 |
| van Oorschot, R | 2 |
| Zethof, T | 1 |
| Bradford, D | 1 |
| Beatty, WW | 2 |
| Dodge, AM | 1 |
| Dodge, LJ | 1 |
| White, K | 1 |
| Panksepp, J | 1 |
| Miczek, KA | 10 |
| Smith, EO | 5 |
| Byrd, LD | 5 |
| Winslow, JT | 1 |
| Essman, EJ | 1 |
| Costello, KB | 1 |
| Berry, SL | 1 |
| Tannhauser, SL | 1 |
| Tannhauser, M | 1 |
| Barros, HM | 1 |
| Corso, CO | 1 |
| Pinto-Netto, LM | 1 |
| Russell, JW | 1 |
| Singer, G | 1 |
| Bowman, G | 1 |
| Emley, GS | 2 |
| Hutchinson, RR | 2 |
| Peffer-Smith, PG | 1 |
| Amery, B | 1 |
| Minichiello, MD | 1 |
| Brown, GL | 1 |
| O'Donnell, JM | 1 |
| Mollenauer, S | 1 |
| White, M | 1 |
| Plotnik, R | 1 |
| Pipkin, B | 1 |
| Bellarosa, A | 1 |
| Bedford, JA | 1 |
| Wilson, MC | 1 |
| Voith, VL | 1 |
| McKinney, WT | 1 |
| Castellanos, FX | 1 |
| Elia, J | 1 |
| Kruesi, MJ | 1 |
| Gulotta, CS | 1 |
| Mefford, IN | 1 |
| Potter, WZ | 1 |
| Ritchie, GF | 1 |
| Rapoport, JL | 1 |
| Haney, M | 2 |
| Field, EF | 1 |
| Pellis, SM | 1 |
| Hine, B | 1 |
| Wallach, MB | 1 |
| Gershon, S | 1 |
| Richmond, JS | 1 |
| Young, JR | 1 |
| Groves, JE | 1 |
| Barr, GA | 3 |
| Gibbons, JL | 3 |
| Bridger, WH | 2 |
| Corson, EO | 2 |
| Corson, SA | 2 |
| Arnold, LE | 3 |
| Knopp, W | 1 |
| Miley, WM | 2 |
| Posner, I | 1 |
| Bierbrauer, B | 1 |
| Scott, JP | 1 |
| Krsiak, M | 1 |
| Pribík, V | 1 |
| Leaf, RC | 1 |
| Wnek, DJ | 1 |
| Lamon, S | 1 |
| Gay, PE | 2 |
| Humber, LG | 2 |
| Bruderlein, FT | 1 |
| Philipp, AH | 2 |
| Götz, M | 1 |
| Voith, K | 1 |
| Marini, JL | 1 |
| Walters, JK | 1 |
| Sheard, MH | 1 |
| Sassenrath, EN | 1 |
| Chapman, LF | 1 |
| Malick, JB | 1 |
| Antelman, SM | 1 |
| Caggiula, AR | 1 |
| Shinn, B | 1 |
| Cole, SO | 1 |
| Mukherjee, BP | 1 |
| Pradhan, SN | 1 |
| Moyer, KE | 2 |
| Allen, RP | 1 |
| Safer, D | 1 |
| Covi, L | 1 |
| Hodge, GK | 1 |
| Butcher, LL | 1 |
| Gianutsos, G | 2 |
| Lal, H | 5 |
| Hynes, MD | 1 |
| Drawbaugh, RB | 1 |
| Abbatiello, ER | 1 |
| Daly, I | 1 |
| Zwirner, PP | 1 |
| Porsolt, RD | 1 |
| Loew, DM | 1 |
| Tu, JB | 1 |
| Hartridge, C | 1 |
| Izawa, J | 1 |
| Vasar, E | 1 |
| Soosaar, A | 1 |
| Harro, J | 1 |
| Lang, A | 1 |
| Tidey, JW | 1 |
| Martin, SP | 1 |
| Cherek, DR | 5 |
| Steinberg, JL | 5 |
| Kelly, TH | 5 |
| Robinson, DE | 2 |
| Spiga, R | 1 |
| Tidey, J | 1 |
| Vatne, T | 1 |
| Weerts, E | 1 |
| DeBold, JF | 1 |
| Sebastian, CS | 1 |
| Päivärinta, P | 1 |
| Korpi, ER | 1 |
| Traversa, U | 1 |
| de Angelis, L | 1 |
| Della Loggia, R | 1 |
| Bertolissi, M | 1 |
| Nardini, G | 1 |
| Vertua, R | 1 |
| Munro, AD | 1 |
| Barker, E | 1 |
| Martinez, TT | 2 |
| Speltz, ML | 1 |
| Varley, CK | 1 |
| Peterson, K | 1 |
| Beilke, RL | 1 |
| Mos, J | 1 |
| Jessen, TG | 1 |
| Robinson, D | 1 |
| Burgio, LD | 1 |
| Page, TJ | 1 |
| Capriotti, RM | 1 |
| Van Osdol, BM | 1 |
| Carlson, L | 1 |
| Holmes, SW | 1 |
| Gylys, JA | 1 |
| Ghielmetti, R | 1 |
| Forrest, GL | 1 |
| Bortner, TW | 1 |
| Bakker, CB | 1 |
| Sofia, RD | 1 |
| Lagerspetz, KY | 1 |
| Lagerspetz, KM | 1 |
| Winsberg, BG | 2 |
| Bialer, I | 3 |
| Kupietz, S | 3 |
| Tobias, J | 1 |
| Wender, PH | 1 |
| McCloskey, K | 1 |
| Snyder, SH | 1 |
| Kirilcuk, V | 1 |
| Press, M | 1 |
| Vergnes, M | 1 |
| Chaurand, JP | 1 |
| Powell, DA | 1 |
| Walters, K | 1 |
| Duncan, S | 1 |
| Holley, JR | 1 |
| Crabtree, JM | 1 |
| Salama, AI | 1 |
| Goldberg, ME | 1 |
| Sorenson, CA | 1 |
| Ellison, GD | 1 |
| Campbell, WE | 1 |
| Puri, SK | 2 |
| Weiss, G | 1 |
| Werry, J | 1 |
| Minde, K | 1 |
| Douglas, V | 1 |
| Sykes, D | 1 |
| Ellinwood, EH | 1 |
| Cohen, S | 1 |
| Winsberg, HG | 1 |
| Boissier, JR | 1 |
| Zebrowska-Lupina, I | 1 |
| Simon, P | 1 |
| Hasselager, E | 1 |
| Rolinski, Z | 1 |
| Randrup, A | 2 |
| Thor, DH | 1 |
| Conners, CK | 1 |
| O'Brien, J | 1 |
| Nesson, B | 1 |
| Smith, N | 1 |
| Soulairac, A | 3 |
| van Steenkiste, JN | 3 |
| van Steenkiste, J | 3 |
| Senault, B | 1 |
| Fog, R | 1 |
| Pakkenberg, H | 1 |
| Welch, BL | 1 |
| Welch, AS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder[NCT00228046] | Phase 4 | 40 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
3 reviews available for dextroamphetamine and Aggression
| Article | Year |
|---|---|
Studying the behavioral effects of drugs in group-living nonhuman primates.
Topics: Aggression; Animals; Behavior, Animal; Callithrix; Cercopithecidae; Chlorocebus aethiops; Dextroamph | 1983 |
Effects of psychostimulants on aggression.
Topics: Adolescent; Aggression; Amphetamine; Animals; Child; Dextroamphetamine; Dogs; Dose-Response Relation | 1975 |
A study of developmental hyperactivity.
Topics: Aggression; Antisocial Personality Disorder; Attention; Behavior Therapy; Child; Child Behavior Diso | 1972 |
13 trials available for dextroamphetamine and Aggression
| Article | Year |
|---|---|
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
Topics: Adolescent; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Atten | 2009 |
D-amphetamine and delinquency: hyperkinesis persisting?
Topics: Adolescent; Adolescent Behavior; Aggression; Antisocial Personality Disorder; Dextroamphetamine; Hum | 1974 |
Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder.
Topics: Aggression; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Doub | 1994 |
Effects of d-amphetamine on human aggressive responding maintained by avoidance of provocation.
Topics: Adolescent; Adult; Aggression; Avoidance Learning; Dextroamphetamine; Dose-Response Relationship, Dr | 1989 |
Effects of d-amphetamine on human aggressive behavior.
Topics: Adolescent; Adult; Aggression; Dextroamphetamine; Emotions; Humans; Male; Reinforcement, Psychology | 1986 |
Effects of d-amphetamine on aggressive responding of normal male subjects.
Topics: Adult; Aggression; Dextroamphetamine; Dose-Response Relationship, Drug; Humans; Male; Social Environ | 1987 |
The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo.
Topics: Achievement; Adolescent; Adult; Aggression; Anxiety; Chlorpromazine; Clinical Trials as Topic; Dextr | 1967 |
Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children.
Topics: Adolescent; Aggression; Anxiety; Brain Damage, Chronic; Child; Child Behavior Disorders; Clinical Tr | 1972 |
Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms.
Topics: Aggression; Amphetamine; Attention; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; | 1972 |
Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs.
Topics: Aggression; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; C | 1973 |
Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children.
Topics: Aggression; Anxiety; Attention; Child; Child Behavior Disorders; Child, Preschool; Clinical Trials a | 1974 |
Studies on the hyperactive child. V. The effects of dextroamphetamine and chlorpromazine on behaviour and intellectual functioning.
Topics: Aggression; Child; Child Behavior Disorders; Chlorpromazine; Clinical Trials as Topic; Dextroampheta | 1968 |
Amphetamine abuse.
Topics: Acetylcholinesterase; Aggression; Amphetamine; Animals; Antisocial Personality Disorder; Behavior, A | 1971 |
95 other studies available for dextroamphetamine and Aggression
| Article | Year |
|---|---|
AMPHETAMINE TOXICITY IN AGGRESSIVE MICE.
Topics: Aggression; Central Nervous System Agents; Dextroamphetamine; Mice; Pharmacology; Toxicology | 1965 |
Long-term voluntary D-amphetamine consumption and behavioral predictors for subsequent D-amphetamine addiction in rats.
Topics: Aggression; Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Choice Behavi | 2004 |
Stimulant-atypical antipsychotic interaction and acute dystonia.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar | 2005 |
Cortisol effects of D-amphetamine relate to traits of fearlessness and aggression but not anxiety in healthy humans.
Topics: Adolescent; Adult; Aggression; Anxiety; Dextroamphetamine; Fear; Female; Humans; Hydrocortisone; Mal | 2006 |
Effects of Cannabis sativa and chlorpromazine on mice as measured by two methods used for evaluation of tranquilizing agents.
Topics: Aggression; Animals; Cannabis; Chlorpromazine; Cornea; Dextroamphetamine; Evaluation Studies as Topi | 1966 |
[Influence of anorectics of the amphetamine series on the behavior of the Siamese warrior fish Betta splendens].
Topics: Aggression; Animals; Appetite Depressants; Behavior, Animal; Chlorphentermine; Dextroamphetamine; Fe | 1966 |
Behavioural effects of psychoactive drugs on agonistic behaviour of male territorial rats (resident-intruder model).
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aggression; Agonistic Behavior; Animals; | 1984 |
Psychomotor stimulants, social deprivation and play in juvenile rats.
Topics: Aggression; Animals; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Relationshi | 1982 |
Ethological analysis of drug action on aggression and defense.
Topics: Aggression; Agonistic Behavior; Animals; Brain; Dextroamphetamine; Drug Evaluation, Preclinical; Eth | 1983 |
Habituation of aggression in mice: pharmacological evidence of catecholaminergic and serotonergic mediation.
Topics: Aggression; Animals; Apomorphine; Behavior, Animal; Catecholamines; Dextroamphetamine; Female; Habit | 1983 |
Contrasting effects of d-amphetamine on affiliation and aggression in monkeys.
Topics: Aggression; Animals; Dextroamphetamine; Dominance-Subordination; Humans; Macaca; Male; Social Behavi | 1984 |
Regional brain serotonin receptor changes in differentially housed mice: effects of amphetamine.
Topics: Aggression; Animals; Brain; Brain Chemistry; Dextroamphetamine; Humans; Male; Mice; Receptors, Serot | 1984 |
Suppression of play fighting by amphetamine: effects of catecholamine antagonists, agonists and synthesis inhibitors.
Topics: Aggression; alpha-Methyltyrosine; Animals; Catecholamines; Chlorpromazine; Clonidine; Dextroamphetam | 1984 |
Effects of carbamazepine or imipramine alone or in association with amphetamine on the fighting time of REM sleep-deprived rats.
Topics: Aggression; Animals; Carbamazepine; Dextroamphetamine; Humans; Imipramine; Male; Rats; Rats, Inbred | 1984 |
Effects of interactions between amphetamine and food deprivation on covariation of muricide, consummatory behaviour and activity.
Topics: Aggression; Animals; Dextroamphetamine; Dose-Response Relationship, Drug; Food Deprivation; Humans; | 1983 |
Unique influences of ten drugs upon post-shock biting attack and pre-shock manual responding.
Topics: Aggression; Animals; Bites and Stings; Caffeine; Chlordiazepoxide; Chlorpromazine; Cocaine; Conditio | 1983 |
Effects of d-amphetamine on self-aggression and posturing in stumptail macaques.
Topics: Aggression; Animals; Behavior, Animal; Dextroamphetamine; Dose-Response Relationship, Drug; Humans; | 1983 |
Aggression in hyperactive boys: response to d-amphetamine.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Double-Blind Me | 1984 |
No tolerance to antiaggressive effect of d-amphetamine in mice.
Topics: Aggression; Animals; Cocaine; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Tolerance; H | 1980 |
Chronic amphetamine: effects on defensive flight in the rat.
Topics: Aggression; Animals; Dextroamphetamine; Escape Reaction; Humans; Male; Motor Activity; Rats; Substan | 1982 |
Sociopharmacology of d-amphetamine in Macaca arctoides.
Topics: Aggression; Animals; Dextroamphetamine; Dose-Response Relationship, Drug; Female; Food; Grooming; Hu | 1980 |
Hyperactivity and hyperkinesis.
Topics: Aggression; Animals; Dextroamphetamine; Dogs; Humans; Hyperkinesis | 1980 |
Pharmacological evidence for catecholamine involvement in animal aggression [proceedings].
Topics: Aggression; Animals; Behavior, Animal; Brain Chemistry; Catecholamines; Cocaine; Dextroamphetamine; | 1981 |
Discussion of paper by Dr. Klaus Miczek [proceedings].
Topics: Aggression; Animals; Behavior, Animal; Cocaine; Dextroamphetamine; Humans; Physostigmine; Saimiri; S | 1981 |
Psychomotor stimulant effects of d-amphetamine, MDMA and PCP: aggressive and schedule-controlled behavior in mice.
Topics: Aggression; Animals; Central Nervous System Stimulants; Conditioning, Operant; Dextroamphetamine; Do | 1994 |
Differential effects of amphetamine on the attack and defense components of play fighting in rats.
Topics: Aggression; Agonistic Behavior; Animals; Arousal; Dextroamphetamine; Dose-Response Relationship, Dru | 1994 |
A new test for aggression in rats without aversive stimulation: differential effects of d-amphetamine and cocaine.
Topics: Aggression; Animals; Behavior, Animal; Cocaine; Dextroamphetamine; Dose-Response Relationship, Drug; | 1979 |
Involvement of biogenic amines in drug-induced aggressive pecking in chicks.
Topics: Aggression; Animals; Animals, Newborn; Antidepressive Agents; Biogenic Amines; Chickens; Dextroamphe | 1975 |
Violent dyscontrol responsive to d-amphetamine.
Topics: Adult; Aggression; Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Humans; Male; R | 1978 |
Inhibition of rat predatory aggression by acute and chronic D- and L-amphetamine.
Topics: Aggression; Amphetamine; Animals; Appetitive Behavior; Depression, Chemical; Dextroamphetamine; Dose | 1977 |
Long-term elimination of violent behaviour by the interaction of psychopharmacologic and psychosocial therapy [proceedings].
Topics: Aggression; Animals; Behavior, Animal; Conditioning, Psychological; Dextroamphetamine; Dogs; Humans; | 1977 |
A behavioral analysis of aggressive behaviors induced and modulated by delta9-tetrahydrocannabinol, pilocarpine, d-amphetamine and l-dopa [proceedings].
Topics: Aggression; Animals; Behavior, Animal; Dextroamphetamine; Dominance-Subordination; Dronabinol; Human | 1977 |
Effects of combining pilocarpine, d-amphetamine, and either a free feeding schedule or cyclic food deprivation on mouse killing by rats.
Topics: Aggression; Animals; Dextroamphetamine; Drug Antagonism; Feeding Behavior; Food Deprivation; Humans; | 1978 |
Animal model for study of hyperkinesis and aggression.
Topics: Aggression; Animals; Dextroamphetamine; Dogs; Humans; Hyperkinesis; Models, Psychological | 1978 |
Effect of amphetamine on sequences of behavioural activities in mice.
Topics: Aggression; Animals; Behavior, Animal; Dextroamphetamine; Dose-Response Relationship, Drug; Female; | 1978 |
Despite various drugs, cats continue to kill mice.
Topics: Aggression; Amitriptyline; Amphetamine; Animals; Avoidance Learning; Cats; Conditioning, Operant; De | 1978 |
Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol.
Topics: Aggression; Animals; Avoidance Learning; Butaclamol; Catalepsy; Dextroamphetamine; Dibenzocyclohepte | 1979 |
Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamol.
Topics: Aggression; Animals; Avoidance Learning; Butaclamol; Catalepsy; Dextroamphetamine; Dibenzocyclohepte | 1979 |
A comparison of the effects of acute and subacute administration of beta-phenylethylamine and d-amphetamine on mouse killing behavior of rats.
Topics: Aggression; Animals; Dextroamphetamine; Feeding Behavior; Humans; Male; Mice; Phenethylamines; Rats; | 1979 |
Effects of d- and l-amphentamine on hypothalamically-elicited movement and attack in the cat.
Topics: Aggression; Amphetamine; Animals; Cats; Dextroamphetamine; Female; Humans; Hypothalamus; Male; Movem | 1979 |
Primate social behavior as a method of analysis of drug action: studies with THC in monkeys.
Topics: Aggression; Alcohol Drinking; Animals; Behavior, Animal; Brain; Cannabis; Dextroamphetamine; Dronabi | 1976 |
Antagonism of isolation-induced aggression in mice by thyrotropin-relasing hormone (TRH).
Topics: Aggression; Amino Acids; Animals; Depression, Chemical; Dextroamphetamine; Humans; Male; Mice; Motor | 1976 |
Norepinephrine-dopamine interactions and behavior.
Topics: Aggression; Animals; Avoidance Learning; Behavior; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulf | 1977 |
Effect of arousal by social isolation, grouping, and d-amphetamine on inter-male aggression in mice (Mus musculus).
Topics: Aggression; Animals; Arousal; Dextroamphetamine; Humans; Male; Mice; Motor Activity; Olfactory Bulb; | 1976 |
Interactions of amygdala lesions with effects of pilocarpine and d-amphetamine on mouse killing, feeding, and drinking in rats.
Topics: Aggression; Amygdala; Animals; Behavior, Animal; Body Weight; Dextroamphetamine; Dose-Response Relat | 1976 |
Effects of lithium on foot shock-induced aggressive behavior in rats.
Topics: Aggression; Animals; Dextroamphetamine; Drug Interactions; Electroshock; Humans; Lithium; Male; Moto | 1976 |
Effects of imipramine, d-amphetamine, and tripelennamine on mouse and frog killing by the rat.
Topics: Aggression; Animals; Appetitive Behavior; Dextroamphetamine; Female; Humans; Imipramine; Male; Mice; | 1976 |
Catecholamine correlates of isolation-induced aggression in mice.
Topics: Aggression; Animals; Apomorphine; Brain Chemistry; Catecholamines; Dextroamphetamine; Disulfiram; Hu | 1975 |
Aggression in mice after p-chloroamphetamine.
Topics: Aggression; Amphetamines; Animals; Dextroamphetamine; Humans; Male; Mice; Motor Activity; p-Chloroam | 1975 |
Paradoxical absence of aggression during naloxone-precipitated morphine withdrawal.
Topics: Aggression; Animals; Apomorphine; Dextroamphetamine; Humans; Male; Morphine Dependence; Naloxone; Ra | 1975 |
Effects of d-amphetamine sulfate on aggressive behavior in laboratory mice.
Topics: Aggression; Animals; Body Weight; Dextroamphetamine; Female; Fertility; Humans; Litter Size; Male; M | 1975 |
Inter-group aggression in mice: a new method for testing the effects of centrally active drugs.
Topics: Aggression; Animals; Atropine; Chlordiazepoxide; Chlorpromazine; Dextroamphetamine; Humans; Imiprami | 1975 |
Psychopharmacogenetic aspects of Prader-Willi syndrome.
Topics: Adolescent; Aggression; Appetite Depressants; Behavior Therapy; Carbamazepine; Combined Modality The | 1992 |
Changes at cholecystokinin receptors induced by long-term treatment with diazepam and haloperidol.
Topics: Aggression; Animals; Behavior, Animal; Ceruletide; Dextroamphetamine; Diazepam; Electroshock; Halope | 1992 |
Heightened aggressive behavior during morphine withdrawal: effects of d-amphetamine.
Topics: Aggression; Animals; Dextroamphetamine; Dose-Response Relationship, Drug; Male; Mice; Morphine; Moto | 1992 |
Effects of dominance rank on d-amphetamine-induced increases in aggression.
Topics: Aggression; Animals; Dextroamphetamine; Macaca; Male; Social Dominance | 1990 |
Effects of acute administration of diazepam and d-amphetamine on aggressive and escape responding of normal male subjects.
Topics: Aggression; Avoidance Learning; Body Weight; Dextroamphetamine; Diazepam; Dose-Response Relationship | 1990 |
Temporal and sequential patterns of agonistic behavior: effects of alcohol, anxiolytics and psychomotor stimulants.
Topics: Aggression; Agonistic Behavior; Animals; Anti-Anxiety Agents; Central Nervous System Stimulants; Dex | 1989 |
Automated method for measuring fighting behavior and locomotor activity of mice.
Topics: Aggression; Animals; Behavior, Animal; Data Collection; Dextroamphetamine; Evaluation Studies as Top | 1989 |
Effects of caffeine and chlor-desmethyldiazepam on fighting behavior of mice with different reactivity baselines.
Topics: Aggression; Animals; Anti-Anxiety Agents; Benzodiazepines; Caffeine; Dextroamphetamine; Diazepam; El | 1985 |
The effects of apomorphine, d-amphetamine and chlorpromazine on the aggressiveness of isolated Aequidens pulcher (Teleostei, Cichlidae).
Topics: Aggression; Animals; Apomorphine; Chlorpromazine; Dextroamphetamine; Female; Fishes | 1986 |
Behavioral contingencies and d-amphetamine effects on human aggressive and non-aggressive responding.
Topics: Aggression; Avoidance Learning; Dextroamphetamine; Dose-Response Relationship, Drug; Humans; Male; P | 1986 |
Comparison of the effect of common decongestant agents and amphetamine on fighting behavior and weight change.
Topics: Aggression; Animals; Body Weight; Dextroamphetamine; Ephedrine; Mice; Phenylephrine; Phenylpropanola | 1988 |
Effects of dextroamphetamine and contingency management on a preschooler with ADHD and oppositional defiant disorder.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child Behavior Disorder | 1988 |
Maternal aggression towards different sized male opponents: effect of chlordiazepoxide treatment of the mothers and d-amphetamine treatment of the intruders.
Topics: Aggression; Animals; Body Constitution; Chlordiazepoxide; Dextroamphetamine; Exploratory Behavior; F | 1987 |
The effect of phenylpropanolamine and amphetamine on fighting behavior and weight change in mice.
Topics: Aggression; Animals; Body Weight; Dextroamphetamine; Mice; Phenylpropanolamine | 1987 |
Clinical behavioral pharmacology: methods for evaluating medications and contingency management.
Topics: Achievement; Adult; Aggression; Attention; Behavior Therapy; Child; Dextroamphetamine; Humans; Intel | 1985 |
d-Amphetamine induced changes in social interaction patterns.
Topics: Aggression; Aging; Animals; Dextroamphetamine; Humans; Macaca; Male; Social Behavior | 1985 |
The central nervous system pharmacology of an anti-emetic dihydroindolone derivative.
Topics: Aggression; Animals; Antiemetics; Apomorphine; Behavior, Animal; Cats; Chlorpromazine; Conditioning, | 1973 |
Sensitivity of aggressive mice to centrally acting drugs.
Topics: Aggression; Animals; Antidepressive Agents; Behavior, Animal; Central Nervous System; Chlorpromazine | 1965 |
Concentrations of amphetamine in the brain in normal or aggressive mice.
Topics: Aggression; Animals; Behavior, Animal; Brain Chemistry; Dextroamphetamine; Humans; Mice | 1965 |
Structural relationship and potency of agents which selectively block mouse killing (muricide) behavior in rats.
Topics: Aggression; Animals; Antidepressive Agents; Behavior, Animal; Central Nervous System Stimulants; Chl | 1969 |
Amphetamine toxicity in genetically aggressive and non-aggressive mice.
Topics: Aggression; Animals; Breeding; Dextroamphetamine; Genetics, Behavioral; Humans; Mice; Selection, Gen | 1971 |
Intraspecies aggression in rats: effects of d-amphetamine and chlordiazepoxide.
Topics: Aggression; Animals; Behavior, Animal; Chlordiazepoxide; Dextroamphetamine; Dose-Response Relationsh | 1974 |
Basis of behavioral influence of chlorpromazine.
Topics: Aggression; Animals; Attention; Behavior, Animal; Chlorpromazine; Depression, Chemical; Dextroamphet | 1972 |
[Amphetaminic activation, hippocampal theta rhythm and rat-mouse interspecific aggression behavior].
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Dextroamphetamine; Dose-Response Relationship, D | 1972 |
The effects of chlorpromazine and d-amphetamine upon shock-elicited aggression.
Topics: Aggression; Animals; Arousal; Behavior, Animal; Chlorpromazine; Dextroamphetamine; Dose-Response Rel | 1973 |
Sex differences in fighting and defense induced in rats by shock and dextro-amphetamine during morphine abstinence.
Topics: Aggression; Animals; Behavior, Animal; Dextroamphetamine; Electroshock; Escape Reaction; Female; Hum | 1973 |
Enhanced locomotor activity following amphetamine in mouse-killing rats.
Topics: Aggression; Animals; Behavior, Animal; Brain; Brain Chemistry; Dextroamphetamine; Dopamine; Humans; | 1973 |
Nonlinear changes in activity and emotional reactivity scores following central noradrenergic lesions in rats.
Topics: Aggression; Animals; Behavior, Animal; Cerebral Ventricles; Dextroamphetamine; Diencephalon; Electro | 1973 |
Behavioral modification of hyperkinetic dogs.
Topics: Administration, Oral; Aggression; Animals; Behavior, Animal; Dextroamphetamine; Dogs; Female; Humans | 1973 |
Reduced threshold to pain induced aggression specifically related to morphine dependence.
Topics: Aggression; Animals; Dextroamphetamine; Drug Synergism; Electroshock; Ethanol; Humans; Male; Morphin | 1974 |
A behavior rating scale for assessing improvement in behaviorally deviant children: a preliminary investigation.
Topics: Adolescent; Aggression; Anxiety; Attention; Child; Child Behavior Disorders; Dextroamphetamine; Diag | 1972 |
[Psychopharmacologic profile of prazepam].
Topics: Aggression; Animals; Avoidance Learning; Benzazepines; Clonidine; Cyclopropanes; Depression, Chemica | 1972 |
Specific antagonism by dopamine inhibitors of items of amphetamine induced aggressive behaviour.
Topics: Aggression; Animals; Aza Compounds; Behavior, Animal; Brain; Butyrophenones; Dextroamphetamine; Dopa | 1972 |
Amphetamine induced fighting during morphine withdrawal.
Topics: Aggression; Animals; Behavior, Animal; Dextroamphetamine; Humans; Male; Morphine; Rats; Social Behav | 1971 |
Review of stimulant drugs in learning and behavior disorders.
Topics: Aggression; Amphetamine; Child; Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; L | 1971 |
Morphine-withdrawal aggression: sensitization by amphetamines.
Topics: Aggression; Amphetamine; Animals; Dextroamphetamine; Humans; Hydroxylamines; Male; Methylphenidate; | 1971 |
Amphetamine-induced aggression in mice pretreated with dihydroxyphenylalanine (DOPA) and-or reserpine.
Topics: Aggression; Animals; Dextroamphetamine; Dihydroxyphenylalanine; Drug Synergism; Humans; Male; Mice; | 1970 |
[Demonstration of participation of adrenergic regulations in some immunitary acquisitions in rats].
Topics: Aggression; Animals; Antibody Formation; Chlorpromazine; Dextroamphetamine; Ergotamine; Humans; Nial | 1970 |
[Demonstration of participation of adrenergic regulations in variations of appetency for alcohol in rats].
Topics: Aggression; Alcohol Drinking; Animals; Chlorpromazine; Dextroamphetamine; Ergotamine; Humans; Nialam | 1970 |
[Intraspecific aggressive behavior induced by apomorphine in the rat].
Topics: Acepromazine; Age Factors; Aggression; Amitriptyline; Animals; Apomorphine; Atropine; Behavior, Anim | 1970 |
Lesions in corpus striatum and cortex of rat brains and the effect on pharmacologically induced stereotyped, aggressive and cataleptic behaviour.
Topics: Aggression; Animals; Basal Ganglia; Behavior, Animal; Catalepsy; Cerebral Cortex; Dextroamphetamine; | 1970 |
[Action of d-amphetamine on acquisition of immunity in rats].
Topics: Aggression; Animals; Dextroamphetamine; Humans; Immunity; Immunization; Rats | 1968 |
Graded effect of social stimulation upon d-amphetamine toxicity, aggressiveness and heart and adrenal weight.
Topics: Adrenal Glands; Aggression; Animals; Behavior, Animal; Catecholamines; Dextroamphetamine; Environmen | 1966 |